Partnerships are a core component of our business growth and diversification strategy, and we have established a diverse portfolio of collaborations with pharmaceutical and biotech companies, government organizations and research institutes. These relationships have enabled us to accelerate the rate of development in our pipeline, as well as to increase the number of product candidates across a wide variety of applications
We are actively seeking partnership opportunities with our lead immuno-oncology candidate, DPX-Survivac, to assess novel combinations in areas of high, unmet medical needs, as well as further clinical development in ovarian cancer and other cancers. We also seek opportunities to deploy our candidate products via licensing collaborations in other hard-to-treat disease areas.
Please note that any proposals that are submitted to IMV via email or via our website will be considered non-confidential. No information exchange may be deemed confidential without a signed confidentiality or disclosure agreement from IMV.